List of Tables
Table 1. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Dose)
Table 7. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2020-2025) & (K Dose)
Table 8. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Region (2026-2031) & (K Dose)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Manufacturers (2020-2025) & (K Dose)
Table 11. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-Related Macular Degeneration (AMD) Treatment Drugs as of 2024)
Table 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Dose)
Table 18. Key Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base and Headquarters
Table 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2020-2025) & (K Dose)
Table 23. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Type (2026-2031) & (K Dose)
Table 24. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Age-Related Macular Degeneration (AMD) Treatment Drugs ASP by Type (2020-2031) & (US$/Dose)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2020-2025) & (K Dose)
Table 29. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales by Application (2026-2031) & (K Dose)
Table 30. Age-Related Macular Degeneration (AMD) Treatment Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Age-Related Macular Degeneration (AMD) Treatment Drugs ASP by Application (2020-2031) & (US$/Dose)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Growth Accelerators and Market Barriers
Table 37. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Growth Accelerators and Market Barriers
Table 40. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (K Dose) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Ionis Pharmaceuticals, Inc Corporation Information
Table 51. Ionis Pharmaceuticals, Inc Description and Major Businesses
Table 52. Ionis Pharmaceuticals, Inc Product Models, Descriptions and Specifications
Table 53. Ionis Pharmaceuticals, Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 54. Ionis Pharmaceuticals, Inc Sales Value Proportion by Product in 2024
Table 55. Ionis Pharmaceuticals, Inc Sales Value Proportion by Application in 2024
Table 56. Ionis Pharmaceuticals, Inc Sales Value Proportion by Geographic Area in 2024
Table 57. Ionis Pharmaceuticals, Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
Table 58. Ionis Pharmaceuticals, Inc Recent Developments
Table 59. Bausch Health Companies Inc Corporation Information
Table 60. Bausch Health Companies Inc Description and Major Businesses
Table 61. Bausch Health Companies Inc Product Models, Descriptions and Specifications
Table 62. Bausch Health Companies Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 63. Bausch Health Companies Inc Sales Value Proportion by Product in 2024
Table 64. Bausch Health Companies Inc Sales Value Proportion by Application in 2024
Table 65. Bausch Health Companies Inc Sales Value Proportion by Geographic Area in 2024
Table 66. Bausch Health Companies Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
Table 67. Bausch Health Companies Inc Recent Developments
Table 68. Regeneron Pharmaceuticals Inc Corporation Information
Table 69. Regeneron Pharmaceuticals Inc Description and Major Businesses
Table 70. Regeneron Pharmaceuticals Inc Product Models, Descriptions and Specifications
Table 71. Regeneron Pharmaceuticals Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 72. Regeneron Pharmaceuticals Inc Sales Value Proportion by Product in 2024
Table 73. Regeneron Pharmaceuticals Inc Sales Value Proportion by Application in 2024
Table 74. Regeneron Pharmaceuticals Inc Sales Value Proportion by Geographic Area in 2024
Table 75. Regeneron Pharmaceuticals Inc Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
Table 76. Regeneron Pharmaceuticals Inc Recent Developments
Table 77. Biogen Corporation Information
Table 78. Biogen Description and Major Businesses
Table 79. Biogen Product Models, Descriptions and Specifications
Table 80. Biogen Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 81. Biogen Sales Value Proportion by Product in 2024
Table 82. Biogen Sales Value Proportion by Application in 2024
Table 83. Biogen Sales Value Proportion by Geographic Area in 2024
Table 84. Biogen Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
Table 85. Biogen Recent Developments
Table 86. Novartis AG Corporation Information
Table 87. Novartis AG Description and Major Businesses
Table 88. Novartis AG Product Models, Descriptions and Specifications
Table 89. Novartis AG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 90. Novartis AG Sales Value Proportion by Product in 2024
Table 91. Novartis AG Sales Value Proportion by Application in 2024
Table 92. Novartis AG Sales Value Proportion by Geographic Area in 2024
Table 93. Novartis AG Age-Related Macular Degeneration (AMD) Treatment Drugs SWOT Analysis
Table 94. Novartis AG Recent Developments
Table 95. Sanofi S.A. Corporation Information
Table 96. Sanofi S.A. Description and Major Businesses
Table 97. Sanofi S.A. Product Models, Descriptions and Specifications
Table 98. Sanofi S.A. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 99. Sanofi S.A. Recent Developments
Table 100. Bayer AG Corporation Information
Table 101. Bayer AG Description and Major Businesses
Table 102. Bayer AG Product Models, Descriptions and Specifications
Table 103. Bayer AG Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 104. Bayer AG Recent Developments
Table 105. Coherus Biosciences Inc Corporation Information
Table 106. Coherus Biosciences Inc Description and Major Businesses
Table 107. Coherus Biosciences Inc Product Models, Descriptions and Specifications
Table 108. Coherus Biosciences Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 109. Coherus Biosciences Inc Recent Developments
Table 110. F. Hoffmann-La Roche Ltd Corporation Information
Table 111. F. Hoffmann-La Roche Ltd Description and Major Businesses
Table 112. F. Hoffmann-La Roche Ltd Product Models, Descriptions and Specifications
Table 113. F. Hoffmann-La Roche Ltd Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 114. F. Hoffmann-La Roche Ltd Recent Developments
Table 115. Apellis Pharmaceuticals Inc Corporation Information
Table 116. Apellis Pharmaceuticals Inc Description and Major Businesses
Table 117. Apellis Pharmaceuticals Inc Product Models, Descriptions and Specifications
Table 118. Apellis Pharmaceuticals Inc Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 119. Apellis Pharmaceuticals Inc Recent Developments
Table 120. AbbVie Corporation Information
Table 121. AbbVie Description and Major Businesses
Table 122. AbbVie Product Models, Descriptions and Specifications
Table 123. AbbVie Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 124. AbbVie Recent Developments
Table 125. Pfizer Inc. Corporation Information
Table 126. Pfizer Inc. Description and Major Businesses
Table 127. Pfizer Inc. Product Models, Descriptions and Specifications
Table 128. Pfizer Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 129. Pfizer Inc. Recent Developments
Table 130. Amgen Inc. Corporation Information
Table 131. Amgen Inc. Description and Major Businesses
Table 132. Amgen Inc. Product Models, Descriptions and Specifications
Table 133. Amgen Inc. Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 134. Amgen Inc. Recent Developments
Table 135. Samsung Bioepis Corporation Information
Table 136. Samsung Bioepis Description and Major Businesses
Table 137. Samsung Bioepis Product Models, Descriptions and Specifications
Table 138. Samsung Bioepis Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)
Table 139. Samsung Bioepis Recent Developments
Table 140. Key Raw Materials Distribution
Table 141. Raw Materials Key Suppliers
Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 143. Milestones in Production Technology Evolution
Table 144. Distributors List
Table 145. Market Trends and Market Evolution
Table 146. Market Drivers and Opportunities
Table 147. Market Challenges, Risks, and Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Age-Related Macular Degeneration (AMD) Treatment Drugs Product Picture
Figure 2. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Aflibercept Product Picture
Figure 4. Ranibizumab Product Picture
Figure 5. Others Product Picture
Figure 6. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Hospital Pharmacy
Figure 8. Retail Pharmacy
Figure 9. Online Pharmacy
Figure 10. Age-Related Macular Degeneration (AMD) Treatment Drugs Report Years Considered
Figure 11. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 13. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Region (2020-2031)
Figure 15. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (2020-2031) & (K Dose)
Figure 16. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales (CAGR) by Region (2020-2031) (K Dose)
Figure 17. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume Market Share in 2024
Figure 19. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Aflibercept Revenue Market Share by Manufacturer in 2024
Figure 22. Ranibizumab Revenue Market Share by Manufacturer in 2024
Figure 23. Others Revenue Market Share by Manufacturer in 2024
Figure 24. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Type (2020-2031)
Figure 25. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Type (2020-2031)
Figure 26. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Market Share by Application (2020-2031)
Figure 27. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue Market Share by Application (2020-2031)
Figure 28. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
Figure 29. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 30. North America Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
Figure 31. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2020- 2031)
Figure 32. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 33. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
Figure 34. North America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 35. US Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 36. Canada Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Mexico Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
Figure 39. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 40. Europe Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
Figure 41. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2020-2031)
Figure 42. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 43. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
Figure 44. Europe Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 45. Germany Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 46. France Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. U.K. Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. Italy Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Russia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
Figure 51. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 52. Asia-Pacific Top 8 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
Figure 53. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2020- 2031)
Figure 54. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 55. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
Figure 56. Asia-Pacific Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 57. Indonesia Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 58. Japan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. South Korea Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. China Taiwan Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. India Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
Figure 63. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Central and South America Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
Figure 65. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2021-2031)
Figure 66. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 67. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
Figure 68. Central and South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 69. Brazil Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
Figure 70. Argentina Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
Figure 71. Middle East, and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales YoY (2020-2031) & (K Dose)
Figure 72. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 73. Middle East and Africa Top 5 Manufacturers Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) in 2024
Figure 74. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Type (2021-2031)
Figure 75. South America Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 76. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Volume (K Dose) by Application (2020-2031)
Figure 77. Middle East and Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 78. GCC Countries Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
Figure 79. Turkey Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. Egypt Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. South Africa Age-Related Macular Degeneration (AMD) Treatment Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. Age-Related Macular Degeneration (AMD) Treatment Drugs Industry Chain Mapping
Figure 83. Regional Age-Related Macular Degeneration (AMD) Treatment Drugs Manufacturing Base Distribution (%)
Figure 84. Global Age-Related Macular Degeneration (AMD) Treatment Drugs Production Market Share by Region (2020-2031)
Figure 85. Age-Related Macular Degeneration (AMD) Treatment Drugs Production Process
Figure 86. Regional Age-Related Macular Degeneration (AMD) Treatment Drugs Production Cost Structure
Figure 87. Channels of Distribution (Direct Vs Distribution)
Figure 88. Bottom-up and Top-down Approaches for This Report
Figure 89. Data Triangulation
Figure 90. Key Executives Interviewed